Search in the Abstract Database

Search Abstracts 2012

* = Presenting author

P218. Effect of infliximab on the level of adhesion molecules in inflammatory bowel disease

L. Lazebnik1, O. Boldyreva1, O. Knyazev1, V. Sagynbaeva2

1Central Research Institute of Gastroenterology, Moscow, Russian Federation; 2Central Scientific Research Institute of Gastroenterology, Moscow, Russian Federation

Background: Intercellular adhesion molecule are involved not only in the distribution of cells at the periphery but also in the processes of cell interactions in the development of the immune response. In the process of settlement, there are two distinct phases: first phase – the interaction of migrating T cells to the endothelium of postcapillary venules and the second stage – the passage through the endothelium into the parenchyma of the organ. The implementation of these steps are involved adhesins different molecules: L‑selectin, E‑selectin, P‑selectin, sVCAM‑1. They cause the migration of cells from the bloodstream into the inflammatory focus, ie contribute to increased inflammatory infiltration of the mucous membrane and homing of lymphocytes. The activity of endothelial cells and their involvement in the development of inflammation are not less important than the effect of the inflammatory infiltrate cells.

Aim: To study the effect of infliximab on the level of adhesion molecules in patients with inflammatory bowel disease (IBD).

Methods: We examined 16 patients with IBD receiving infliximab, including 7 patients with ulcerative colitis (UC) and Crohn's disease in 9 patients (CD). Age of patients ranged from 17 to 68 years, mean age – 40.3. The diagnosis of UC and BC data confirmed the clinical, laboratory, histological, and instrumental methods. Before and after treatment with infliximab to determine the level of adhesion molecules L‑selectin, E‑selectin, P‑selectin, sVCAM‑1 in serum by ELISA using test kits “Bender MedSystems” (Austria).

Results: The level of L‑selectin before starting treatment with infliximab was 9.9±0.6 ng/ml, E‑selectin – 8.5±1.4 ng/ml, P‑selectin-11.3±0.8 ng/ml, sVCAM-1–17.3±5.8 ng/ml. The level of P‑selectin, E‑selectin, sVCAM‑1 after treatment significantly decreased to 8.9±1.0 ng/ml, 5.5±1.7 ng/ml and 9.5±4.4 ng/ml, respectively (p < 0.001). The concentration of L‑selectin after treatment with infliximab was 9.6±0.8 ng/ml (p = 0.26).

Conclusions: Thus, as a result of the study with infliximab in patients with inflammatory bowel disease. significantly reduces the level of P‑selectin, E‑selectin and sVCAM‑1, but does not affect the concentration of L‑selectin.